002653.SHE Xizang Haisco Pharmaceutical Group Co Ltd
- Market cap
- CNY 62.5B
- P/E
- 46.1x
- P/B
- 10.50x
- ROE
- 30.8%
- Dividend yield
- 0.53%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002653.SHE undervalued?
Graham numberThe Graham number of Xizang Haisco Pharmaceutical Group Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Xizang Haisco Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Xizang Haisco Pharmaceutical Group Co Ltd yet.
Xizang Haisco Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Xizang Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research collaboration with Eli Lilly and Company to develop medicines across multiple the…
Full company profileXizang Haisco Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Xizang Haisco Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.44B | 1.86B | 3.43B | 3.94B | 3.33B | 2.77B | 3.02B | 3.36B | 3.72B | 4.39B | 6.63B |
| Gross Profit | 1.06B | 1.20B | 1.93B | 2.59B | 2.26B | 1.83B | 2.09B | 2.38B | 2.66B | 3.12B | 5.33B |
| Operating Income | 332M | 266M | 324M | 547M | 699M | 512M | 364M | 314M | 507M | 324M | 1.94B |
| EBITDA | 322M | 172M | 235M | 411M | 333M | 184M | 317M | 544M | 498M | 584M | 1.91B |
| Net Income | 443M | 238M | 333M | 494M | 637M | 345M | 277M | 295M | 395M | 260M | 1.84B |
| EPS | 0.41 | 0.22 | 0.31 | 0.46 | 0.60 | 0.32 | 0.26 | 0.27 | 0.35 | 0.23 | 1.61 |
| Balance Sheet | |||||||||||
| Total Assets | 3.74B | 4.11B | 4.37B | 5.04B | 5.00B | 5.01B | 6.05B | 6.65B | 6.80B | 7.01B | 9.01B |
| Total Liabilities | 1.50B | 2.14B | 2.37B | 2.66B | 2.15B | 2.09B | 2.91B | 2.48B | 2.60B | 2.72B | 3.06B |
| Shareholders' Equity | 2.25B | 1.99B | 2.03B | 2.37B | 2.90B | 2.84B | 3.04B | 4.18B | 4.21B | 4.29B | 5.96B |
| Cash & Short-term Investments | 1.18B | 1.10B | 998M | 1.22B | 824M | 575M | 775M | 1.33B | 1.21B | 1.39B | 2.58B |
| Total Debt | 802M | 600M | 905M | 730M | 1.08B | 915M | 1.80B | 966M | 1.17B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 409M | 392M | 473M | 764M | 206M | 35.8M | 94.5M | 450M | 442M | 786M | - |
| Capital Expenditure | 208M | 393M | 352M | 583M | 602M | 703M | 700M | 391M | 441M | 332M | 393M |
| Free Cash Flow | 218M | -1.45M | 121M | 182M | -396M | -667M | -606M | 58.6M | 1.39M | 454M | 1.01B |
| Ratios | |||||||||||
| ROE | 19.7% | 12.0% | 16.4% | 20.8% | 21.9% | 12.1% | 9.1% | 7.1% | 9.4% | 6.1% | 30.8% |
| ROA | 11.8% | 5.8% | 7.6% | 9.8% | 12.7% | 6.9% | 4.6% | 4.4% | 5.8% | 3.7% | 20.4% |
| Net Profit Margin | 30.8% | 12.8% | 9.7% | 12.5% | 19.1% | 12.4% | 9.2% | 8.8% | 10.6% | 5.9% | 27.7% |
| Debt to Equity | 0.36x | 0.30x | 0.45x | 0.31x | 0.37x | 0.32x | 0.59x | 0.23x | 0.28x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Xizang Haisco Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 0.53%
- Forward dividend
- 0.79 CNY
- Payout ratio
- 128.3%
- Ex-dividend date
- Sep 4, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 333M | 0.30 | 128.3% |
| 2024 | CNY 422M | 0.38 | 106.7% |
| 2023 | CNY 42.6M | 0.04 | 14.4% |
| 2022 | CNY 247M | 0.23 | 89.3% |
| 2021 | CNY 426M | 0.40 | 123.5% |
| 2020 | CNY 131M | 0.12 | 20.5% |
| 2019 | CNY 203M | 0.19 | 41.1% |
| 2018 | CNY 326M | 0.30 | 97.8% |
| 2017 | CNY 510M | 0.47 | 214.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.35:1 on Sep 12, 2013.
Who owns Xizang Haisco Pharmaceutical Group Co Ltd
- Insiders 74.48%
- Institutions 11.56%
- Public & others 13.97%
- Shares outstanding 1.14B
- Free float 267M
Xizang Haisco Pharmaceutical Group Co Ltd company profile
- Company name
- Xizang Haisco Pharmaceutical Group Co Ltd
- Ticker
- 002653.SHE
- ISIN
- CNE100001BC7
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 29, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,597
- Fiscal year end
- December
- Address
- No. 17 Sanxiang Avenue, Shannan, China, 856000
- Phone
- 86 89 3783 4865
- Website
- haisco.com
About Xizang Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research collaboration with Eli Lilly and Company to develop medicines across multiple therapeutic areas. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Shannan, China.
Xizang Haisco Pharmaceutical Group Co Ltd management
5- Mr. Pangke YanGM & Director · born 1980
- Ms. Peng DuanChief Financial Officer · born 1977
- Mr. Meng WangDeputy GM & Board Secretary · born 1986
- Da Guo TanAccounting Supervisor
- Mr. Rui Bin WangDeputy General Manager · born 1962